# Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)

Study · id `cardio:ct-nct02831088` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02831088](<https://clinicaltrials.gov/study/NCT02831088>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02831088

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

## Technical summary

Registry record NCT02831088. Randomized; triple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT02831088, source copy `cardio:ctgov-nct02831088-2017-07-13`, retrieved 2026-10-26)
- Start date: 2016-07 (registry gives no type) (ClinicalTrials.gov record NCT02831088, source copy `cardio:ctgov-nct02831088-2017-07-13`, retrieved 2026-10-26)
- Primary completion: 2018-12-30 (anticipated) (ClinicalTrials.gov record NCT02831088, source copy `cardio:ctgov-nct02831088-2017-07-13`, retrieved 2026-10-26)
- Completion: 2018-12-30 (anticipated) (ClinicalTrials.gov record NCT02831088, source copy `cardio:ctgov-nct02831088-2017-07-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02831088, source copy `cardio:ctgov-nct02831088-2017-07-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02831088-2017-07-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
- Acronym: SONIC
- Condition: Ischemic Stroke
- Intervention (Drug): Neu2000KWL High-does group
- Intervention (Drug): Neu2000KWL Low-does group
- Intervention (Drug): Placebo
- Lead sponsor: GNT Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: GNT Pharma (`cardio:org-gnt-pharma`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial (`cardio:pubmed-36065810`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d77ff4ab4082983fced211ac87f7b1abcbc188819e69b614e9dfd90934fa62ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
